申请人：成都百利多特生物药业有限责任公司 拟定适应症（或功能主治）：本品适用于既往经 PD-1/PD-L1 单抗联合含铂化 疗治疗失败的复发性或转移性食管鳞癌患者。 拟优先审评的理由：经审核，本申请符合《药品注册管理办法》和《国家药 监局关于发布〈突破性治疗药物审评工作程序（试行）〉等三个文件的公告》（2020 年第 82 号）有关要求，同意按优先审评范围"（四）纳入突破性治疗药物程序的 药品"纳入优先审评审批程序。 四川百利天恒药业股份有限公司 自愿披露关于 iza-bren（EGFR×HER3 双抗 ADC）用于治疗 复发性或转移性食管鳞癌被纳入优先审评程序的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，四川百利天恒药业股份有限公司（以下简称"公司"）自主研发的全 球首创（First-in-class）、新概念（New concept）且唯一进入 III 期临床阶段的 EGFR ×HER3 双抗 ADC（注射用 iza-bren）被国家药品监督管理局药品审评中心（以下 简称"CDE"）纳入优先审评品种名单 ...

Core Viewpoint - Bailitianheng (688506.SH) has announced that its self-developed, first-in-class, and new concept EGFR×HER3 dual antibody ADC (injectable iza-bren) has been included in the priority review list by the National Medical Products Administration's Center for Drug Evaluation (CDE) [1] Group 1 - The drug iza-bren is the world's first EGFR×HER3 dual antibody ADC to be included in the priority review list [1]

Core Viewpoint - Baili Tianheng (688506.SH) announced that its self-developed first-in-class EGFR×HER3 dual antibody ADC (injectable iza-bren) has been included in the priority review list by the National Medical Products Administration (NMPA) [1] Group 1: Product Development - Iza-bren is the world's first EGFR×HER3 dual antibody ADC to be included in the priority review list [1] - The proposed indication for iza-bren is for patients with recurrent or metastatic esophageal squamous cell carcinoma who have failed previous treatment with PD-1/PD-L1 monoclonal antibodies combined with platinum-based chemotherapy [1] Group 2: Clinical Progress - As of now, iza-bren has been included in the breakthrough therapy list by the CDE for treating recurrent or metastatic esophageal squamous cell carcinoma after failure of PD-1/PD-L1 monoclonal antibody therapy [1] - The interim analysis of the Phase III clinical trial for treating esophageal squamous cell carcinoma has achieved dual primary endpoints of progression-free survival (PFS) and overall survival (OS) [1] - Iza-bren has two indications that have been included in the priority review list by the CDE [1]

Core Viewpoint - The company, Bai Li Tian Heng, has announced that its self-developed drug, iza-bren, a first-in-class EGFR×HER3 dual antibody ADC, has been included in the priority review list by the National Medical Products Administration's Center for Drug Evaluation (CDE) [1] Group 1 - Iza-bren is the world's first EGFR×HER3 dual antibody ADC to enter the Phase III clinical stage [1] - The inclusion in the priority review list signifies a significant milestone for the company and its innovative drug development [1]

Group 1 - The core point of the article highlights that in December 2025, the worst-performing ordinary equity and mixed funds were both managed by Baoying Fund, specifically the Baoying Medical Health Hong Kong-Shenzhen Stock A and C, which reported returns of -13.20% and -13.26% respectively [1] - The Baoying Innovation Medical Mixed Initiation A and C funds also performed poorly, with returns of -14.14% and -14.19%, making them the worst in the mixed fund category [1] - All these funds are themed around the medical sector and are managed by the same fund manager, Yao Yi, who has a background in research and fund management [1] Group 2 - The latest quarterly report indicates that the top ten holdings of the Baoying Medical Health Hong Kong-Shenzhen Stock fund include major companies such as Innovent Biologics, Kelun Pharmaceutical, and others, while the Baoying Innovation Medical Mixed Initiation fund shares many of the same top holdings [1][2] - Notably, several of these top holdings experienced significant declines in December, with the largest holding, Innovent Biologics, dropping by 18.97%, and another major holding, 3SBio, declining by over 22% [2] - The performance metrics of the funds show that the Baoying Innovation Medical Mixed Initiation C has a cumulative net value of 0.8857 and a scale of 0.51 billion, while the A share has a cumulative net value of 0.8886 and a scale of 0.47 billion [3]

Core Viewpoint - In December 2025, 15 funds managed by GF Fund experienced a decline of over 8%, with the GF Healthcare Mixed Fund A and C managed by Wu Xingwu leading the losses at -13.3% and -13.27% respectively [1][2]. Fund Performance Summary - The GF Healthcare Mixed Fund A and C have recorded a decline of 41.19% and 42.41% respectively since their inception on October 21, 2020 [1]. - The top ten holdings of the GF Healthcare Mixed Fund include companies such as Kelun-Botai Biotech, Innovent Biologics, and WuXi AppTec [1]. - Other funds managed by Wu Xingwu, including GF Hong Kong-Shenzhen Healthcare Mixed Fund A and C, also reported significant declines in December [2][3]. Additional Fund Details - The GF Healthcare Mixed Fund A had a unit net value of 0.5881 as of January 5, 2026, with a one-month decline of -6.59% and a one-year return of 38.28% [2]. - The GF Healthcare Mixed Fund C had a unit net value of 0.5759 as of January 5, 2026, with a one-month decline of -6.62% and a one-year return of 37.74% [2]. - Other funds with notable declines include the GF Medical Innovation Mixed Fund A and C, which fell by -12.79% and -12.75% respectively [3][4].

Group 1 - The first round of domestic oil price adjustment in 2026 is expected to be suspended, with the adjustment window opening on January 6 at 24:00. In 2025, domestic oil prices experienced 25 rounds of adjustments, ending with three consecutive declines, resulting in a decrease of 915 yuan per ton for gasoline and 880 yuan per ton for diesel compared to the end of 2024. The price adjustment situation for 2026 may become "zero increase, zero decrease, one suspension" [1] Group 2 - A press conference will be held by the State Council Information Office on January 6 at 3 PM to introduce the promotion of green consumption, featuring officials from the Ministry of Commerce, the Ministry of Ecology and Environment, the Ministry of Agriculture and Rural Affairs, and the State Administration for Market Regulation [2] Group 3 - The 2026 Harbin International Ice and Snow Economic Expo will take place from January 6 to 8 at the Harbin International Convention and Exhibition Center, featuring 28 planned activities across various fields such as ice and snow equipment, technology, finance, and cultural tourism, aimed at showcasing the achievements of Harbin's ice and snow economy and promoting international cooperation [3] Group 4 - On January 6, a total of 6 companies will have their restricted shares unlocked, with a total of 797 million shares being released, amounting to a market value of 102.903 billion yuan based on the latest closing prices. The companies with the largest unlock volumes include Baili Tianheng (298 million shares), Xinwufeng (233 million shares), and Aiyu Co., Ltd. (227 million shares) [4] Group 5 - On January 6, 70 companies disclosed progress on stock repurchases, with 76 related announcements. Two companies announced stock repurchase plans for the first time, one plan was approved by a shareholders' meeting, 59 companies reported on the implementation of repurchase plans, and 8 companies completed their repurchase plans. The highest repurchase amounts were announced by Aidi Precision (up to 200 million yuan) and Kelun Pharmaceutical (up to 100 million yuan) [5] Group 6 - Seven A-shares will undergo equity registration on January 6, with all seven companies planning to distribute dividends. The companies with the largest dividend payouts include Hai'an Group (20.00 yuan per 10 shares), Tongfei Co., Ltd. (2.00 yuan per 10 shares), and Chongqing Bank (1.68 yuan per 10 shares) [6] Group 7 - Nine A-shares disclosed progress on private placements on January 6, with two companies announcing new private placement plans, three plans approved by shareholders' meetings, three plans approved by the CSRC, and one plan halted. The highest fundraising amounts from the latest disclosed plans were from Guangyun Da (up to 1.211 billion yuan) and Haopeng Technology (up to 800 million yuan) [7]

Core Viewpoint - On January 6, a total of 10 listed companies had their restricted shares unlocked, with a total market value of approximately 49.768 billion yuan [1] Group 1: Companies and Their Unlocking Details - Aishuxin Co., Ltd. (爱旭股份) had 227 million shares unlocked, categorized as newly issued A-shares for institutional placement [1] - Xinwufeng Co., Ltd. (新五丰) had 244 million shares unlocked, also categorized as newly issued A-shares for institutional placement [1] - Dun'an Environment Co., Ltd. (盾安环境) had 139 million shares unlocked, categorized as newly issued A-shares for institutional placement [1] - Pulite Co., Ltd. (普利特) had 988,300 shares unlocked, categorized as shares from equity incentive plans [1] - Samsung Medical (三星医疗) had 2.1793 million shares unlocked, categorized as shares from equity incentive plans [1] - Kailong Co., Ltd. (凯龙股份) had 174,900 shares unlocked, categorized as shares from equity incentive plans [1] - Shengbang Co., Ltd. (盛帮股份) had 30.662 million shares unlocked, categorized as extended lock-up period shares [1] - Yujing Co., Ltd. (宇晶股份) had 26 million shares unlocked, categorized as newly issued A-shares for institutional placement [1] - Zhongyi Technology (中亦科技) had 53.145 million shares unlocked, categorized as extended lock-up period shares [1] - Baili Tianheng (百利天恒) had 30.9 million shares unlocked, with no specific category mentioned [1]

从解禁市值来看，百利天恒、爱旭股份、新五丰解禁市值居前，解禁市值分别为965.37亿元、30.3亿 元、13.68亿元。 从解禁股数占总股本比例来看，百利天恒、林泰新材、新五丰解禁比例居前，解禁比例分别为72.2%、 25.41%、18.62%。 每经AI快讯，Wind数据显示，周二（1月6日），共有6家公司限售股解禁，合计解禁量为7.97亿股，按 最新收盘价计算，合计解禁市值为1029.03亿元。 从解禁量来看，百利天恒、新五丰、爱旭股份解禁量居前，解禁股数分别为2.98亿股、2.33亿股、2.27 亿股。 ...

12月31日，百利天恒涨0.14%，成交额2.20亿元。两融数据显示，当日百利天恒获融资买入额894.29万 元，融资偿还2943.23万元，融资净买入-2048.94万元。截至12月31日，百利天恒融资融券余额合计3.54 亿元。 融资方面，百利天恒当日融资买入894.29万元。当前融资余额3.50亿元，占流通市值的1.05%，融资余 额超过近一年90%分位水平，处于高位。 融券方面，百利天恒12月31日融券偿还400.00股，融券卖出672.00股，按当日收盘价计算，卖出金额 21.71万元；融券余量1.20万股，融券余额387.59万元，超过近一年70%分位水平，处于较高位。 资料显示，四川百利天恒药业股份有限公司位于四川省成都市温江区成都海峡两岸科技产业园百利路 161号一幢一号,香港湾仔皇后大道东183号合和中心46楼，成立日期2006年8月17日，上市日期2023年1 月6日，公司主营业务涉及药品的研发、生产及销售。主营业务收入构成为：在某一时点确认99.57%， 在某一时段内确认0.43%。 责任编辑：小浪快报 截至9月30日，百利天恒股东户数5979.00，较上期增加25.08%；人均流通股1 ...